Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Brain Research

• Publication date

  1994-10-31

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/0006-8993(94)90796-XPMID 7859092
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A sensitive and inexpensive high-performance liquid chromatographic assay for tyrosine hydroxylase

  2005cited by this paper
• Wearing‐off fluctuations in Parkinson's disease: Contribution of postsynaptic mechanisms

  1994cited by this paper
• On-off effects of dopamine receptor agonists in the hemi-parkinsonian rat.

  1993cited by this paper
• Striatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson's disease.

  1993cited by this paper
• Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease.

  1992cited by this paper
• “Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease

  1991cited by this paper
• Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior.

  1991cited by this paper
• Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats.

  1991cited by this paper
• Induction of chorea and dystonia in parkinsonian primates

  1990cited by this paper
• Dopaminergic cells align along radial glia in the developing mesencephalon of the rat.

  1990cited by this paper
• Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization

  1990cited by this paper
• Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists.

  1989cited by this paper
• Does levodopa aggravate Parkinson's disease?

  1988cited by this paper
• Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II

  1988cited by this paper
• Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, Part I

  1988cited by this paper
• Receptor changes during chronic dopaminergic stimulation.

  1988cited by this paper
• Assay for tyrosine hydroxylase in hypothalamic homogenates using high-performance liquid chromatography with electrochemical detection.

  1987cited by this paper
• On‐off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics

  1987cited by this paper
• Multi‐center study of Parkinson mortality with early versus later dopa treatment

  1987cited by this paper
• Episodic unresponsiveness to single doses of L‐dopa in parkinsonian fluctuators

  1986cited by this paper
• Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease.

  1986cited by this paper
• Determination of dopamine, norepinephrine, serotonin and their major metabolic products in rat brain by reverse-phase ion-pair high performance liquid chromatography with electrochemical detection.

  1985cited by this paper
• Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)

  1985cited by this paper
• The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.

  1984cited by this paper
• Should Levodopa Therapy for Parkinsonism be Started Early or Late? Evidence Against Early Treatment

  1984cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983cited by this paper
• Behavioural and biochemical changes following chronic administration of L-dopa to rats.

  1982cited by this paper
• Fluctuations of disability in Parkinson's disease – clinical aspects

  1981cited by this paper
• The relationship between loss of dopamine nerve terminals, striatal [3H]spiroperidol binding and rotational behavior in unilaterally 6-hydroxydopamine-lesioned rats.

  1981cited by this paper
• Turning behaviour in animals.

  1980cited by this paper
• Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization.

  1980cited by this paper
• Dopamine receptor mechanisms: behavioral and electrophysiological studies.

  1978cited by this paper
• Success and problems of long-term levodopa therapy in Parkinson's disease.

  1977cited by this paper
• Letter: Hepanosticon in screening for HBsAg.

  1975cited by this paper
• Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system.

  1971cited by this paper
• L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.

  1969cited by this paper

• Striatal GluN2A gene suppression reduces L-DOPA-induced abnormal involuntary movements in parkinsonian rats.

  2025cites this paper
• Construct, Face, and Predictive Validity of Parkinson’s Disease Rodent Models

  2024cites this paper
• Gray matter atrophy in a 6-OHDA-induced model of Parkinson's disease.

  2024cites this paper
• Assessing changes in whole-brain structural connectivity in the unilateral 6-hydroxydopamine rat model of Parkinson’s disease using diffusion imaging and tractography

  2024cites this paper
• The Management of Parkinson’s Disease: An Overview of the Current Advancements in Drug Delivery Systems

  2023cites this paper
• Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson’s disease

  2022cites this paper
• Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease.

  2022cites this paper
• Phosphodiesterase 9 inhibition prolongs the antiparkinsonian action of l-DOPA in parkinsonian non-human primates.

  2022cites this paper
• Simultaneous Measurement of Striatal Dopamine and Hydrogen Peroxide Transients Associated with L-DOPA Induced Rotation in Hemiparkinsonian Rats

  2021cites this paper
• Medical treatment of the motor features of Parkinson disease

  2021cites this paper
• Modeling synucleinopathies in rodents

  2021cites this paper
• Transcriptomic approach predicts a major role for transforming growth factor beta type 1 pathway in L‐Dopa‐induced dyskinesia in parkinsonian rats

  2020cites this paper
• [Safinamide Mesilate (Equfina® TABLETS 50 mg): preclinical and clinical pharmacodynamics, efficacy, and safety].

  2020cites this paper
• The voiding efficiency in rat models with dopaminergic brain lesions induced through unilateral and bilateral intrastriatal injections

  2020cites this paper
• Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on l-DOPA-induced dyskinesia in parkinsonian rats

  2020cites this paper
• Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects

  2019cites this paper
• Change of Extracellular Glutamate Level in Striatum during Deep Brain Stimulation of the Entopeduncular Nucleus in Rats

  2019cites this paper
• Tat‐Src reduced NR2B tyrosine phosphorylation and its interaction with NR2B in levodopa‐induced dyskinetic rats model

  2019cites this paper
• The Rodent Models of Dyskinesia and Their Behavioral Assessment

  2019cites this paper
• Classic animal models of Parkinson's disease: a historical perspective.

  2019cites this paper
• Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia

  2018cites this paper
• Selegiline increases on time without exacerbation of dyskinesia in 6‐hydroxydopamine‐lesioned rats displaying l‐Dopa‐induced wearing‐off and abnormal involuntary movements

  2018cites this paper
• Interactions of the tricyclic antidepressant drug amitriptyline with L‐DOPA in the striatum and substantia nigra of unilaterally 6‐OHDA‐lesioned rats. Relevance to motor dysfunction in Parkinson's disease

  2018cites this paper
• S-nitrosylation of Src by NR2B-nNOS signal causes Src activation and NR2B tyrosine phosphorylation in levodopa-induced dyskinetic rat model

  2018cites this paper
• A Selective Phosphodiesterase 10A Inhibitor Reduces L‐Dopa‐Induced Dyskinesias in Parkinsonian Monkeys

  2018cites this paper
• Putaminal dopamine depletion in de novo Parkinson's disease predicts future development of wearing-off.

  2018cites this paper
• Animal models of l-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse

  2018cites this paper
• Animal models of l‐dopa‐induced dyskinesia in Parkinson's disease

  2018cites this paper
• Striatal Glutamate and GABA after High Frequency Subthalamic Stimulation in Parkinsonian Rat

  2017cites this paper
• Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson’s disease

  2017cites this paper
• Validation of a New Scoring Scale for Behavioral Assessment of L-Dopa-Induced Dyskinesia in the Rat: A New Tool for Early Decision-Making in Drug Development.

  2017cites this paper
• Study of the Neuropeptide Function in Parkinson’s Disease Using the 6-Hydroxydopamine Model of Experimental Hemiparkinsonism

  2017cites this paper
• Repetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model

  2016cites this paper
• Targeting the D1-N-methyl-d-aspartate receptor complex reduces l-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats

  2016influential citation
• Ibuprofen or piroxicam protects nigral neurons and delays the development of l-dopa induced dyskinesia in rats with experimental Parkinsonism: Influence on angiogenesis.

  2016cites this paper
• CHARACTERIZATION OF GREY MATTER ATROPHY FOLLOWING 6-HYDROXYDOPAMINE LESION OF THE NIGROSTRIATAL SYSTEM

  2016cites this paper
• Treatment of the later stages of Parkinson’s disease – pharmacological approaches now and in the future

  2015cites this paper
• NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model.

  2015cites this paper
• Adenosine A2A Receptor Antagonists in L-DOPA-Induced Motor Fluctuations

  2015cites this paper
• In vivo evaluation of the dopaminergic neurotransmission system using [123I]FP-CIT SPECT in 6-OHDA lesioned rats.

  2015cites this paper
• A Critical Evaluation of Behavioral Rodent Models of Motor Impairment Used for Screening of Antiparkinsonian Activity: The Case of Adenosine A2A Receptor Antagonists

  2014cites this paper
• Modeling dyskinesia in animal models of Parkinson disease.

  2014cites this paper
• Preclinical Models of Levodopa-Induced Dyskinesia

  2014cites this paper
• The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats

  2014cites this paper
• Rodent Models of Treatment-Related Complications in Parkinson Disease

  2014cites this paper
• Postsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat models

  2014cites this paper
• Modeling Parkinson's disease in monkeys for translational studies, a critical analysis.

  2014cites this paper
• The cB 1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK 1 / 2 phosphorylation in 6-OhDa-lesioned rats

  2014cites this paper
• Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson's disease.

  2013cites this paper
• Animal models of Parkinson’s disease and related disorders

  2013cites this paper
• Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.

  2013cites this paper
• Wearing‐off phenomena and levodopa‐induced dyskinesias in posttraumatic hemiparkinsonism

  2013influential citation
• l‐dopa‐induced dyskinesias in unilateral 6‐hydroxydopamine‐lesioned rats are not modified by excitotoxic lesion of the entopeduncular nucleus and substantia nigra pars reticulata

  2013cites this paper
• Dopamine deficiency increases synchronized activity in the rat subthalamic nucleus.

  2012cites this paper
• Mathematical Insights into the Effects of Levodopa

  2012cites this paper
• Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease

  2012cites this paper
• Brain drug delivery systems for neurodegenerative disorders.

  2012cites this paper
• Unpredictable rotational responses to L-dopa in the rat model of Parkinson's disease: the role of L-dopa pharmacokinetics and striatal dopamine depletion.

  2012cites this paper
• Animal models of L-DOPA-induced dyskinesia: an update on the current options.

  2012cites this paper
• Neurotoxin-based models of Parkinson's disease.

  2012cites this paper
• Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.

  2012cites this paper
• The Significance of Continuous Dopaminergic Stimulation in the Treatment of Parkinson’s Disease

  2012cites this paper
• Disruption of programmed masticatory movements in unilateral MPTP-treated monkeys as a model of jaw movement abnormality in Parkinson’s disease

  2012cites this paper
• Subcutaneous Apomorphine Infusion - An Update

  2012cites this paper
• The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats.

  2012cites this paper
• Deuterium-L-DOPA: a Novel Means to Improve Treatment of Parkinson's Disease

  2012cites this paper
• Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

  2011cites this paper
• Role of nitric oxide in motor control: implications for Parkinson's disease pathophysiology and treatment.

  2011cites this paper
• Optimisation and mechanistic insights of dyskinesia in rodent models of Parkinson’s disease

  2011cites this paper
• Nitric Oxide Synthase Inhibitor Improves De Novo and Long-Term l-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats

  2011cites this paper
• In vivo magnetic resonance imaging characterization of bilateral structural changes in experimental Parkinson’s disease: a T2 relaxometry study combined with longitudinal diffusion tensor imaging and manganese‐enhanced magnetic resonance imaging in the 6‐hydroxydopamine rat model

  2011influential citation
• The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats.

  2011cites this paper
• The metabotropic glutamate receptor antagonist 2‐methyl‐6‐(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L‐dopa‐induced dyskinesias

  2011cites this paper
• GluR1 Phosphorylation and Persistent Expression of Levodopa-induced Motor Response Alterations in the Hemi-Parkinsonian Rat

  2011cites this paper
• In vivo 6-OHDA-induced neurodegeneration and nigral autophagic markers expression.

  2011cites this paper
• Rodent Models of l -DOPA-Induced Dyskinesia

  2011cites this paper
• Context-driven changes in L-DOPA-induced behaviours in the 6-OHDA lesioned rat.

  2011influential citation
• The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates

  2010cites this paper
• Effect of Cdk5 Antagonist on L-Dopa-Induced Dyskinesias in a Rat Model of Parkinson's Disease

  2010cites this paper
• Cortical oscillations scan using chirp-evoked potentials in 6-hydroxydopamine rat model of Parkinson's disease.

  2010cites this paper
• Striatal Overexpression of ΔFosB Reproduces Chronic Levodopa-Induced Involuntary Movements

  2010cites this paper
• Adult cell therapy for brain neuronal damages and the role of tissue engineering.

  2010cites this paper
• Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.

  2010cites this paper
• Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.

  2010cites this paper
• Catechol-O-methyltransferase inhibitors in preclinical models as adjuncts of L-dopa treatment.

  2010cites this paper
• The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.

  2010cites this paper
• When Do Levodopa Motor Fluctuations First Appear in Parkinson’s Disease?

  2010cites this paper
• Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats.

  2010cites this paper
• The scientific and clinical basis for the treatment of Parkinson disease (2009)

  2009cites this paper
• Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats

  2009cites this paper
• Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances

  2009cites this paper
• Rodent models of treatment-induced motor complications in Parkinson's disease.

  2009cites this paper
• Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats

  2009cites this paper
• Striatal glutamatergic mechanisms and extrapyramidal movement disorders

  2009cites this paper
• Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats

  2009cites this paper
• Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.

  2009cites this paper
• Quantitative autoradiographic study on receptor regulation in the basal ganglia in rat model of levodopa-induced motor complications

  2009cites this paper
• Cellules stromales mésenchymateuses et vecteurs polymériques pour l'ingénierie tissulaire du système nerveux central

  2009cites this paper
• Comparative Effects of Acute or Chronic Administration of Levodopa to 6-OHDA-lesioned Rats on the Expression and Phosphorylation of N-methyl-d-aspartate Receptor NR1 Subunits in the Striatum

  2009cites this paper
• Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats

  2009influential citation